Kiora Pharmaceuticals, Inc.

NasdaqCM:KPRX Stok Raporu

Piyasa değeri: US$11.7m

Kiora Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Brian Strem

İcra Kurulu Başkanı

US$971.7k

Toplam tazminat

CEO maaş yüzdesi59.91%
CEO görev süresi4.8yrs
CEO sahipliği1.4%
Yönetim ortalama görev süresiVeri yok
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Analiz Makalesi • May 21

Why Kiora Pharmaceuticals' (NASDAQ:KPRX) Earnings Are Better Than They Seem

Shareholders appeared to be happy with Kiora Pharmaceuticals, Inc.'s ( NASDAQ:KPRX ) solid earnings report last week...
Seeking Alpha • Oct 13

Kiora pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Kiora Pharmaceuticals (NASDAQ:KPRX) has received a letter from Nasdaq on October 12, 2022 informing the company that it has regained compliance with the minimum bid price requirement. Kiora was previously notified by Nasdaq on February 23, 2022 that it was not in compliance with the minimum bid price rule.
Seeking Alpha • Sep 26

Kiora Pharma announces 1-for-40 reverse stock split

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX), a biotech focused on treatments for eye disorders, announced Monday that the company’s shareholders authorized a reverse stock split of the common stock. Accordingly, the KPRX board has approved a decision to implement a reverse stock split of one share of common stock for every 40 shares, and the company shares will begin trading on Nasdaq on a split-adjusted basis on Sep. 27. KPRX shares added ~10% pre-market after the announcement. The reverse stock split is expected to reduce KPRX’s total outstanding common shares to ~1.1M with no impact on authorized shares and par value which will remain at 50M and $0.01, respectively. Kiora (KPRX) shares have plunged ~90% over the past 12 months underperforming the broader maker, as shown in this graph.
Seeking Alpha • Aug 12

Kiora Pharmaceuticals reports 1H results

Kiora Pharmaceuticals press release (NASDAQ:KPRX): 1H Net loss for the first half of 2022 was $6.0 million compared to $4.6 million for the first half of 2021. Cash and cash equivalents were $2.4 million as of June 30, 2022 with $1.1 million in prepaid expenses for research and development activities. Subsequent to the end of the first half, Kiora raised an additional $5.3 million in net proceeds from a public offering Shares +8.8% PM.
Seeking Alpha • Jul 28

Kiora gets US patent for KIO-201 use with antibiotics for eye wound healing

Kiora Pharmaceuticals (NASDAQ:KPRX) said it was granted a U.S. patent covering hydrogel-based sustained release platforms, including KIO-201, which helps in controlled release of antibiotics to treat eye diseases. The Salt Lake City-based company added that the patent — No. 11,376,214 — relates to non-blurring, antibiotic-containing hydrogel compositions which have an extended contact time on the eye and have potential to improve the health of the ocular surface for accelerated wound healing. Kiora noted that KIO-201 is a chemically modified form of the natural polymer hyaluronic acid, formulated as an eye drop aimed to accelerate natural corneal wound healing. "In addition to potentially repairing corneal wounds as a standalone treatment, we see opportunities to employ our technology in combination with antibiotics to further accelerate wound healing and reduce post-surgical complications, including infections," said Kiora President and CEO Brian Strem.
Seeking Alpha • Jul 22

Kiora Pharmaceuticals prices $5.2M underwritten public offering

Kiora Pharmaceuticals (NASDAQ:KPRX) prices an underwritten public offering for gross proceeds of ~$5.2M prior to deducting underwriting discounts and commissions and offering expenses. Underwriters' have a 45-day option to purchase up to ~3.93M additional shares. Closing expected to take place on or about July 26, 2022.
Seeking Alpha • Jul 05

Kiora begins enrolling in phase 2 trial of wound healing eye drops KIO-201

Kiora Pharmaceuticals (NASDAQ:KPRX) said it enrolled the first patient as a part of a phase 2 trial of its eye drops KIO-201 to treat patients with Persistent Corneal Epithelial Defect (PCED). PCED is a rare ocular surface condition characterized by non-healing wounds on the eye surface. KIO-201 is a chemically modified form of the natural polymer hyaluronic acid aimed to accelerate natural corneal wound healing, according to the company's July 5 press release. The study will enroll 10 patients who will be evaluated at 28 days after receiving KIO-201 six times daily. The trial's goals are to evaluate safety and tolerability︎, and the percentage of patients with corneal healing and the associated time to healing.

CEO Tazminat Analizi

Brian Strem'un ücretlendirmesi Kiora Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Mar 31 2026n/an/a

-US$11m

Dec 31 2025US$972kUS$582k

-US$11m

Sep 30 2025n/an/a

-US$9m

Jun 30 2025n/an/a

-US$12m

Mar 31 2025n/an/a

-US$12m

Dec 31 2024US$955kUS$490k

US$4m

Sep 30 2024n/an/a

US$6m

Jun 30 2024n/an/a

US$3m

Mar 31 2024n/an/a

US$2m

Dec 31 2023US$805kUS$416k

-US$13m

Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$714kUS$400k

-US$14m

Sep 30 2022n/an/a

-US$17m

Jun 30 2022n/an/a

-US$15m

Mar 31 2022n/an/a

-US$15m

Dec 31 2021US$659kUS$169k

-US$14m

Tazminat ve Piyasa: Brian 'nin toplam tazminatı ($USD 971.70K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 638.05K ).

Tazminat ve Kazançlar: Brian şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Brian Strem (45 yo)

4.8yrs
Görev süresi
US$971,696
Tazminat

Dr. Brian M. Strem, Ph D., is Co-Founder and Director at Okogen, Inc. He served as Principal Financial and Accounting Officer of Kiora Pharmaceuticals, Inc. since June 16, 2022. He serves as President, Dir...

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Brian Strem
President4.8yrsUS$971.70k1.37%
$ 160.2k
Lisa Walters-Hoffert
Independent Director1.8yrsUS$131.82k0.028%
$ 3.3k
Praveen Tyle
Independent Chairman of the Board17.9yrsUS$189.91k0.11%
$ 13.2k
Carmine Stengone
Independent Director2.8yrsUS$122.44k0.028%
$ 3.3k
Aron Shapiro
Director5.1yrsUS$103.69k0.068%
$ 7.9k
Allen Ho
Member of Scientific Advisory Boardno dataVeri yokVeri yok
David Hollander
Independent Director4.4yrsUS$113.69k0%
$ 0
Mark Pennesi
Member of Scientific Advisory Board3.1yrsVeri yokVeri yok
Roger Goldberg
Member of Scientific Advisory Board1.9yrsVeri yokVeri yok
Erin Parsons
Non-Employee Independent Director4.3yrsUS$128.69k0.12%
$ 13.9k
Christine Kay
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Charlie Wykoff
Member of Scientific Advisory Boardno dataVeri yokVeri yok
4.3yrs
Ortalama Görev Süresi
49yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: KPRX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/21 09:47
Gün Sonu Hisse Fiyatı2026/05/21 00:00
Kazançlar2026/03/31
Yıllık Kazançlar2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Kiora Pharmaceuticals, Inc. 2 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Keay NakaeChardan Capital Markets, LLC
Michael OkunewitchMaxim Group